DNER and neuroblastoma: Moreover, given the mechanism underlying synergy between C16 and BET inhibitors, we would expect this combination to be effective in other wild-type p53 cancer settings where WINi are active, such as neuroblastoma (Bryan et al., 2020) and rhabdoid tumors (Florian et al., 2022).